Imaging Findings and Literature Review of 18F-FDG PET/CT in Primary Systemic AL Amyloidosis

Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci. 2001;356:203–10. discussion 10–1.

Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009;36:702–14.

Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012;7:1337–46.

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid. 2014;21:35–44.

Baqir M, Lowe V, Yi ES, Ryu JH. 18F-FDG PET scanning in pulmonary amyloidosis. J Nucl Med. 2014;55:565–8.

Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine. 2002;69:538–45.

Glaudemans AW, Slart RH, Noordzij W, Dierckx RA, Hazenberg BP. Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging. 2013;40:1095–101.

Son YM, Choi JY, Bak CH, Cheon M, Kim YE, Lee KH, et al. 18F-FDG PET/CT in primary AL hepatic amyloidosis associated with multiple myeloma. Korean J Radiol. 2011;12:634–7.

Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271–83.

de Haro-del Moral FJ, Sanchez-Lajusticia A, Gomez-Bueno M, Garcia-Pavia P, Salas-Anton C, Segovia-Cubero J. Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol (Engl Ed). 2012;65:440–6.

Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4:659–70.

Seo JH, Lee SW, Ahn BC, Lee J. Pulmonary amyloidosis mimicking multiple metastatic lesions on 18F- FDG PET/CT. Lung Cancer. 2010;67:376–9.

Mekinian A, Jaccard A, Soussan M, Launay D, Berthier S, Federici L, et al. 18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review. Amyloid. 2012;19:94–8.

Jeong J, Kong E, Chun K, Cho I. The impact of energy substrates, hormone level and subject-related factors on physiologic myocardial 18F-FDG uptake in normal humans. Nucl Med Mol Imaging. 2013;47:225–31.

Costantino F, Loeuille D, Dintinger H, Pere P, Chary-Valckenaere I. Fixed digital contractures revealing light-chain amyloidosis. Joint Bone Spine. 2009;76:553–5.

Grubstein A, Shitrit D, Sapir EE, Cohen M, Kramer MR. Pulmonary amyloidosis: detection with PET-CT. Clin Nucl Med. 2005;30:420–1.

Kung J, Zhuang H, Yu JQ, Duarte PS, Alavi A. Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med. 2003;28:975–6.

Mainenti PP, Segreto S, Mancini M, Rispo A, Cozzolino I, Masone S, et al. Intestinal amyloidosis: two cases with different patterns of clinical and imaging presentation. World J Gastroenterol. 2010;16:2566–70.

Mekinian A, Ghrenassia E, Pop G, Roberts S, Prendki V, Stirnemann J, et al. Visualization of amyloid arthropathy in light-chain systemic amyloidosis on 18F-FDG PET/CT scan. Clin Nucl Med. 2011;36:52–3.

Ollenberger GP, Knight S, Tauro AJ. False-positive FDG positron emission tomography in pulmonary amyloidosis. Clin Nucl Med. 2004;29:657–8.

Tan H, Guan Y, Zhao J, Lin X. Findings of pulmonary amyloidosis on dual phase FDG PET/CT imaging. Clin Nucl Med. 2010;35:206–7.

Yadav S, Sharma S, Gilfillan I. Unusual positron emission tomography findings in pulmonary amyloidosis: a case report. J Cardiothorac Surg. 2006;1:32.

Yoshida A, Borkar S, Singh B, Ghossein RA, Schoder H. Incidental detection of concurrent extramedullary plasmacytoma and amyloidoma of the nasopharynx on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. J Clin Oncol. 2008;26:5817–9.

Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.

Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508–13.

Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol. 2003;56:406–11.

Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab. 2002;282:E1163–71.

Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006;48:2225–31.

Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, Vellenga E, Haagsma EB, Posthumus MD, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007;48:865–72.

Park CH, Kim HS, Shin HY, Kim HC. Hepatic uptake of Tc-99 m MDP on bone scintigraphy from intravenous iron therapy (Blutal). Clin Nucl Med. 1997;22:762–4.

Currie GP, Rossiter C, Dempsey OJ, Legge JS. Pulmonary amyloid and PET scanning. Respir Med. 2005;99:1463–4.

Soussan M, Ouvrier MJ, Pop G, Galas JL, Neuman A, Weinmann P. Tracheobronchial FDG uptake in primary amyloidosis detected by PET/CT. Clin Nucl Med. 2011;36:723–4.